Stuart Conway, PhD

The Conway Group has an interest in the development of small molecules that modulate cancer-relevant epigenetic targets. They also have a strong interest in the development of hypoxia target pro-drugs and probes that enable imaging of the tumor microenvironment. 

L. D. Wallabregue, H. Bolland, S. Faulkner, E. M. Hammond, S. J. Conway. Two color imaging of different hypoxia levels in cancer cells. J. Am. Chem. Soc., 2023, 145, 2572.

R. Sekirnik, J. K. Reynolds, L. See, J. P. Bluck, A. R. Scorah, C. Tallant, B. Lee, K. B. Leszczynska, R. L. Grimley, R. I. Storer, M. Malattia, S. Crespillo, S. Caria, S. Duclos, E. M. Hammond, S. Knapp, G. M. Morris, F. Duarte, P. C. Biggin, S. J. Conway. Identification of Histone Peptide Binding Specificity and Small-Molecule Ligands for the TRIM33α and TRIM33β Bromodomains. ACS Chem. Biol., 2022, 17, 2753.

M. Brand, J. Clayton, M. Moroglu, M. Schiedel, S. Picaud, J. P. Bluck, A. Skwarska, A. K. N. Chan, C. M. C. Laurin, A. R. Scorah, K. F. L. See, T. P. C. Rooney, O. Fedorov, G. Perell, W. A. Cortopassi, K. E. Christensen, R. I. Cooper, R. S. Paton, W. C. K. Pomerantz, P. C. Biggin, E. M. Hammond, P. Filippakopoulos, S. J. Conway. Controlling intramolecular interactions to develop selective, high-affinity ligands for the CREBBP bromodomain. J. Med. Chem., 2021, 64, 10102.

Skwarska, E. D. D. Calder, I. N. Mistry, D. Sneddon, S. J. Conway, E. M. Hammond. Development and pre-clinical testing of a novel hypoxia-activated pan KDAC inhibitor. Cell Chemical Biology, 2021, 28, 1258.

N. Favalli, G. Bassi, C. Pellegrino, J. Millul, R. De Luca, S. Cazzamalli, S. Yang, A. Trenner, N. Mozzafari, R. Myburgh, M.Moroglu, S. J. Conway, A. Sartori, M. M. Manz, R. A. Lerner, P. Vogt, J. Scheuermann, D. Neri. Stereo- and regio-defined DNA-encoded chemical libraries enable efficient ligand discovery for conditional CAR-T cell activation and for tumor targeting. Nature Chem., 2021, 13, 540.